Skip to main content
OpenTrials
Completed

NCT Number: NCT05108285

Dark Halo and MNV: a Study Between ICGA and OCTA

The aim of study is to compare the evaluation of dark halo area of macular neovascularization (MNV) between indocyanine green angiography (ICGA) and optical coherence tomography angiography (OCTA) in order to identify OCTA as effective and useful biomarker in MNV

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Macular Neovascularisation

Age range

55 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Naples "Federico II"

Naples, 80100, Italy

About this study

Dark halo is defined as a dark perilesional of flow decrease due to an area of reduced choroidal flow adjacent to the macular neovascularization (MNV).

The detection of MNV vascular details was only possible through invasive dye injection, such as fluorescein angiography (FA) or indocyanine green angiography (ICGA).

Optical coherence tomography angiography (OCTA) is a recent imaging technique that is able to detect the perfusion and non-perfusion areas carefully.

The aim of study is to compare the evaluation of dark halo area of MNV between ICGA and OCTA

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age older than 55 years
  • diagnosis of macular neovascularization
  • absence of previous treatment with anti-Vegf injections
  • absence of other retinal vascular diseases

Exclusion criteria

  • age younger than 55 years
  • absence diagnosis of macular neovascularization
  • presence of previous treatment with anti-Vegf injections
  • presence of other retinal vascular diseases

Treatment and study plan

Optical Coherence Tomography Angiography (OCTA) and indocyanine green angiography (ICGA)

Diagnostic Test

OCTA and ICGA is able to detect the dark halo as a area of reduced perfusion around MVN

Primary outcomes

  1. Dark halo measurement

    Time frame: three years

    The OCTA and ICGA parameters analyzed are: the area of dark halo (mm2) that surrounds the coroidal neovascularization.

Sponsors and collaborators

Lead sponsor

Federico II University

Other

Registry information

Official study title

Dark Halo a New Biomarker in Macular Neovascularization: a Comparative Study Between ICGA and OCTA

Important dates

Study start
2018
Primary completion
2020
Study completion
2020
First posted
Nov 4, 2021
Registry last updated
Nov 17, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.